<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gountas, I.</style></author><author><style face="normal" font="default" size="100%">Sypsa, V</style></author><author><style face="normal" font="default" size="100%">Papatheodoridis, G.</style></author><author><style face="normal" font="default" size="100%">Souliotis, K.</style></author><author><style face="normal" font="default" size="100%">Athanasakis, K.</style></author><author><style face="normal" font="default" size="100%">Razavi, H.</style></author><author><style face="normal" font="default" size="100%">Hatzakis, A</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals</style></title><secondary-title><style face="normal" font="default" size="100%">World J Gastroenterol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">World journal of gastroenterology</style></alt-title><short-title><style face="normal" font="default" size="100%">World journal of gastroenterologyWorld journal of gastroenterology</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Cost-Benefit Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">*Health Care Costs</style></keyword><keyword><style  face="normal" font="default" size="100%">Antiviral Agents/economics/pharmacology/*therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">Cost of Illness</style></keyword><keyword><style  face="normal" font="default" size="100%">Cost Savings</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Eradication/*economics/methods/organization &amp; administration</style></keyword><keyword><style  face="normal" font="default" size="100%">Feasibility Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Greece</style></keyword><keyword><style  face="normal" font="default" size="100%">Health Knowledge, Attitudes, Practice</style></keyword><keyword><style  face="normal" font="default" size="100%">Health Plan Implementation/economics/organization &amp; administration</style></keyword><keyword><style  face="normal" font="default" size="100%">Health Services Needs and Demand/economics</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepacivirus/drug effects/isolation &amp; purification</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis C/economics/*prevention &amp; control/virology</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Insurance Coverage/economics</style></keyword><keyword><style  face="normal" font="default" size="100%">Insurance, Health/economics</style></keyword><keyword><style  face="normal" font="default" size="100%">Mass Screening/economics/organization &amp; administration</style></keyword><keyword><style  face="normal" font="default" size="100%">Patient Education as Topic/economics</style></keyword><keyword><style  face="normal" font="default" size="100%">Quality-Adjusted Life Years</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Mar 21</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">11</style></number><volume><style face="normal" font="default" size="100%">25</style></volume><pages><style face="normal" font="default" size="100%">1327-1340</style></pages><isbn><style face="normal" font="default" size="100%">2219-2840 (Electronic)1007-9327 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND: Hepatitis C virus (HCV) is a leading cause of worldwide liver-related morbidity and mortality. The World Health Organization released an integrated strategy targeting HCV-elimination by 2030. This study aims to estimate the required interventions to achieve elimination using updated information for direct-acting antiviral (DAA) treatment coverage, to compute the total costs (including indirect/societal costs) of the strategy and to identify whether the elimination strategy is cost-effective/cost-saving in Greece. AIM: To estimate the required interventions and subsequent costs to achieve HCV elimination in Greece. METHODS: A previously validated mathematical model was adapted to the Greek HCV-infected population to compare the outcomes of DAA treatment without the additional implementation of awareness or screening campaigns versus an HCV elimination strategy, which includes a sufficient number of treated patients. We estimated the total costs (direct and indirect costs), the disability-adjusted life years and the incremental cost-effectiveness ratio using two different price scenarios. RESULTS: Without the implementation of awareness or screening campaigns, approximately 20000 patients would be diagnosed and treated with DAAs by 2030. This strategy would result in a 19.6% increase in HCV-related mortality in 2030 compared to 2015. To achieve the elimination goal, 90000 patients need to be treated by 2030. Under the elimination scenario, viremic cases would decrease by 78.8% in 2030 compared to 2015. The cumulative direct costs to eliminate the disease would range from 2.1-2.3 billion euros (euro) by 2030, while the indirect costs would be euro1.1 billion. The total elimination cost in Greece would range from euro3.2-3.4 billion by 2030. The cost per averted disability-adjusted life year is estimated between euro10100 and euro13380, indicating that the elimination strategy is very cost-effective. Furthermore, HCV elimination strategy would save euro560-895 million by 2035. CONCLUSION: Without large screening programs, elimination of HCV cannot be achieved. The HCV elimination strategy is feasible and cost-saving despite the uncertainty of the future cost of DAAs in Greece.</style></abstract><accession-num><style face="normal" font="default" size="100%">30918426</style></accession-num><notes><style face="normal" font="default" size="100%">Gountas, IliasSypsa, VanaPapatheodoridis, GeorgeSouliotis, KyriakosAthanasakis, KostasRazavi, HomieHatzakis, Angeloseng2019/03/29 06:00World J Gastroenterol. 2019 Mar 21;25(11):1327-1340. doi: 10.3748/wjg.v25.i11.1327.</style></notes><custom2><style face="normal" font="default" size="100%">6429341</style></custom2><auth-address><style face="normal" font="default" size="100%">Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece.Department of Gastroenterology, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens 11527, Greece.Faculty of Social and Political Sciences, University of Peloponnese, Korinthos 20100, Greece.Department of Health Economics, National School of Public Health, Athens 11521, Greece.Center for Disease Analysis, Lafayette, CO 80026, United States.</style></auth-address></record></records></xml>